scholarly journals Proteomic Profiling of Plasma-Derived Biomarkers in Patients with Bladder Cancer: A Step towards Clinical Translation

Life ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 1294
Author(s):  
Taoufik Nedjadi ◽  
Nada Albarakati ◽  
Hicham Benabdelkamel ◽  
Afshan Masood ◽  
Assim A. Alfadda ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Early Detection ◽  
Disease Progression ◽  
Apolipoprotein A1 ◽  
Differentially Expressed ◽  
2D Electrophoresis ◽  
Differentially Expressed Proteins ◽  
Invasive Phenotype ◽  
Cancer Pathogenesis ◽  
Muscle Invasive

Background: Bladder cancer is a life-threatening disease and a major cause of cancer-associated complications. The main challenges confronted during the clinical management of bladder cancer are associated with recurrence and disease progression to the muscle-invasive phenotype. Improved early detection of the disease is of paramount importance to prevent disease progression and improve survival. Hence, novel clinically applicable biomarkers for early detection are warranted. Methods: In the current study, a comparative proteomic approach was undertaken using plasma samples to identify protein biomarkers associated with the muscle-invasive phenotype of bladder carcinoma. Isolated plasma proteins were depleted, DIGE-labeled, then subjected to conventional 2D electrophoresis followed by mass spectrometry for identification of differentially expressed proteins. Western blot was used for data validation. Results: Fourteen differentially expressed proteins with statistically significant changes in abundance between the cancer group and control group were identified. Three differentially expressed proteins were selected for validation, among which apolipoprotein A1 exhibited high specificity and sensitivity (AUC = 0.906). Ingenuity pathway analysis identified IFN-γ and TNF-α as the main signaling hub for the differentially regulated proteins. Conclusion: Our findings provide additional insight into understanding bladder cancer pathogenesis. Our data identified potential non-invasive plasma-derived biomarker proteins that merit additional investigation to validate its clinical usefulness to prevent bladder cancer progression.

scholarly journals Three-gene signature predicts disease progression of non-muscle invasive bladder cancer

2011 ◽  
Vol 2 (4) ◽  
pp. 679-684 ◽  
Author(s):  
PILDU JEONG ◽  
YUN-SOK HA ◽  
IN-CHANG CHO ◽  
SEOK-JOONG YUN ◽  
EUN SANG YOO ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Gene Signature ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer

2011 ◽  
Vol 17 (5-6) ◽  
pp. 478-485 ◽  
Author(s):  
Wun-Jae Kim ◽  
Seon-Kyu Kim ◽  
Pildu Jeong ◽  
Seok-Joong Yun ◽  
In-Chang Cho ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Gene Signature ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer

2011 ◽  
Vol 105 (4) ◽  
pp. 425-430 ◽  
Author(s):  
Chunri Yan ◽  
Young-Won Kim ◽  
Yun-Sok Ha ◽  
Isaac Yi Kim ◽  
Yong-June Kim ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals Mitofusin-2 Down-Regulation Predicts Progression of Non-Muscle Invasive Bladder Cancer

Diagnostics ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1500
Author(s):  
Antonella Cormio ◽  
Gian Maria Busetto ◽  
Clara Musicco ◽  
Francesca Sanguedolce ◽  
Beppe Calò ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Bladder Tumor ◽  
Bladder Wall ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Mitofusin 2 ◽  
Clinical Issue ◽  
Expression Levels ◽  
Muscle Invasive

Identification of markers predicting disease outcome is a major clinical issue for non-muscle invasive bladder cancer (NMIBC). The present study aimed to determine the role of the mitochondrial proteins Mitofusin-2 (Mfn2) and caseinolytic protease P (ClpP) in predicting the outcome of NMIBC. The study population consisted of patients scheduled for transurethral resection of bladder tumor upon the clinical diagnosis of bladder cancer (BC). Samples of the main bladder tumor and healthy-looking bladder wall from patients classified as NMIBC were tested for Mfn2 and ClpP. The expression levels of these proteins were correlated to disease recurrence, progression. Mfn2 and ClpP expression levels were significantly higher in lesional than in non-lesional tissue. Low-risk NMIBC had significantly higher Mfn2 expression levels and significantly lower ClpP expression levels than high-risk NMIBC; there were no differences in non-lesional levels of the two proteins. Lesional Mfn2 expression levels were significantly lower in patients who progressed whereas ClpP levels had no impact on any survival outcome. Multivariable analysis adjusting for the EORTC scores showed that Mfn2 downregulation was significantly associated with disease progression. In conclusion, Mfn2 and ClpP proteins were found to be overexpressed in BC as compared to non-lesional bladder tissue and Mfn2 expression predicted disease progression.

scholarly journals A 5-lncRNA Signature Associated with Smoking Predicts the Overall Survival of Patients with Muscle-Invasive Bladder Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Haoyue Sheng ◽  
Guiming Zhang ◽  
Yongqiang Huang ◽  
Lijiang Sun ◽  
Guohai Shi ◽  
...  
Keyword(s):  
Overall Survival ◽  
Bladder Cancer ◽  
High Risk ◽  
Tobacco Smoke ◽  
Gene Set Enrichment Analysis ◽  
Differentially Expressed ◽  
Invasive Bladder Cancer ◽  
Risk Scores ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Increasing evidence demonstrated that noncoding RNA is abnormally expressed in cancer tissues and serves a vital role in tumorigenesis, tumor development, and metastasis. The aim of the present study was to determine an lncRNA signature in order to predict the overall survival (OS) of patients with muscle-invasive bladder cancer (MIBC). A total of 246 patients with pathologically confirmed MIBC in The Cancer Genome Atlas (TCGA) dataset were recruited and included in the present study. We choose patients who have smoked less (including never smoking) or more than 15 years. A total of 44 differentially expressed lncRNAs were identified with a fold change larger than 1.5 and a P value < 0.05 through the limma package. Subsequently, a comparison between patients with no tobacco smoke exposure for <15 years and patients who had been exposed to tobacco smoke for >15 years was performed by using the matchIt package. Among the 44 differentially expressed lncRNAs, 5 lncRNAs were identified to be significantly associated with OS. Based on the characteristic risk scores of these 5 lncRNAs, patients were divided into low-risk and high-risk groups and exhibited significant differences in OS. Multivariate Cox regression analysis demonstrated that the 5-lncRNA signature was independent of age, tumor-node metastasis (TNM) staging, lymphatic node status, and adjuvant postoperative radiotherapy. In the present study, a novel 5-lncRNA signature was developed and was demonstrated to be useful in predicting the survival of patients with MIBC. If validated, this lncRNA signature may assist in the selection of a high-risk subpopulation that requires more aggressive therapeutic intervention. The risk scores involved in several associated pathways were identified using gene set enrichment analysis (GSEA). However, the clinical implications and mechanism of these 5 lncRNAs require further investigation.

Sign in / Sign up

Export Citation Format

Share Document